{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:51:18Z","timestamp":1793757078723,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40265-022-01790-4","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T08:06:23Z","timestamp":1667549183000},"page":"1549-1556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Relugolix\/Estradiol\/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids"],"prefix":"10.1007","volume":"82","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"1790_CR1","doi-asserted-by":"publisher","first-page":"16043","DOI":"10.1038\/nrdp.2016.43","volume":"2","author":"EA Stewart","year":"2016","unstructured":"Stewart EA, Laughlin-Tommaso SK, Catherino WH, et al. Uterine fibroids. Nat Rev Dis Prim. 2016;2:16043.","journal-title":"Nat Rev Dis Prim"},{"issue":"14","key":"1790_CR2","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMra1209993","volume":"369","author":"SE Bulun","year":"2013","unstructured":"Bulun SE. Uterine fibroids. N Engl J Med. 2013;369(14):1344\u201355.","journal-title":"N Engl J Med"},{"issue":"10","key":"1790_CR3","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/1471-0528.14640","volume":"124","author":"EA Stewart","year":"2017","unstructured":"Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501\u201312.","journal-title":"BJOG"},{"issue":"9252","key":"1790_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(00)03622-9","volume":"357","author":"EA Stewart","year":"2001","unstructured":"Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293\u20138.","journal-title":"Lancet"},{"issue":"6","key":"1790_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/s-0037-1607264","volume":"35","author":"A Al-Hendy","year":"2017","unstructured":"Al-Hendy A, Myers ER, Stewart E. Uterine fibroids: burden and unmet medical need. Semin Reprod Med. 2017;35(6):473\u201380.","journal-title":"Semin Reprod Med."},{"key":"1790_CR6","unstructured":"U.S. Food and Drug Administration. Myfembree: clinical review (NDA 214846). 2021. https:\/\/www.accessdata.fda.gov\/. Accessed 21 Sept 2022."},{"key":"1790_CR7","unstructured":"European Medicines Agency. Ryeqo: Committee for Medicinal Products for Human Use assessment report. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ryeqo-epar-public-assessment-report_en.pdf. Accessed 21 Sept 2022."},{"issue":"1","key":"1790_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.maturitas.2014.06.002","volume":"79","author":"FR Perez-Lopez","year":"2014","unstructured":"Perez-Lopez FR, Ornat L, Ceausu I, et al. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106\u201316.","journal-title":"Maturitas"},{"issue":"7","key":"1790_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJMoa2008283","volume":"384","author":"A Al-Hendy","year":"2021","unstructured":"Al-Hendy A, Lukes AS, Poindexter AN III, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630\u201342.","journal-title":"N Engl J Med"},{"issue":"4","key":"1790_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1056\/NEJMoa1904351","volume":"382","author":"WD Schlaff","year":"2020","unstructured":"Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328\u201340.","journal-title":"N Engl J Med"},{"key":"1790_CR11","unstructured":"Myovant Sciences Inc. Myfembree\u00ae (relugolix, estradiol, and norethindrone acetate) tablets, for oral use: US prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214846s000lbl.pdf. Accessed 21 Sept 2022."},{"key":"1790_CR12","unstructured":"European Medicines Agency. Ryeqo 40 mg\/1 mg\/0.5 mg film-coated tablets: EU summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ryeqo-epar-product-information_en.pdf. Accessed 21 Sept 2022."},{"issue":"14","key":"1790_CR13","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1021\/jm200216q","volume":"54","author":"K Miwa","year":"2011","unstructured":"Miwa K, Hitaka T, Imada T, et al. Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2011;54(14):4998\u20135012.","journal-title":"J Med Chem"},{"key":"1790_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2013.12.001","volume":"723","author":"D Nakata","year":"2014","unstructured":"Nakata D, Masaki T, Tanaka A, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014;723:167\u201374.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1790_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/PL00004180","volume":"11","author":"PD Delmas","year":"2000","unstructured":"Delmas PD, Confavreux E, Garnero P, et al. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int. 2000;11(2):177\u201387.","journal-title":"Osteoporos Int"},{"issue":"3","key":"1790_CR16","first-page":"373","volume":"96","author":"RJ Kurman","year":"2000","unstructured":"Kurman RJ, Felix JC, Archer DF, et al. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol. 2000;96(3):373\u20139.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"1790_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12905-021-01475-2","volume":"21","author":"H Hoshiai","year":"2021","unstructured":"Hoshiai H, Seki Y, Kusumoto T, et al. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial. BMC Womens Health. 2021;21(1):375.","journal-title":"BMC Womens Health"},{"issue":"3","key":"1790_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","volume":"133","author":"Y Osuga","year":"2019","unstructured":"Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019;133(3):423\u201333.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"1790_CR19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","volume":"112","author":"Y Osuga","year":"2019","unstructured":"Osuga Y, Enya K, Kudou K, et al. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019;112(5):922-9.e2.","journal-title":"Fertil Steril"},{"key":"1790_CR20","first-page":"i267","volume":"32","author":"A Lukes","year":"2017","unstructured":"Lukes A, Johnson B, Jones L, et al. Pharmacokinetics, pharmacodynamics, and safety of relugolix, a potent oral once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist, as monotherapy and in combination with estradiol\/norethindrone acetate add-back therapy [abstract]. Hum Reprod. 2017;32:i267\u20138.","journal-title":"Hum Reprod"},{"key":"1790_CR21","unstructured":"Duijkers I, Klipping C, Draeger C, et al. Suppression of ovarian activity during co-administration of the oral gonadotropin-releasing hormone receptor antagonist relugolix, estradiol, and norethindrone acetate in healthy female volunteers [abstract no. P-287]. Hum Reprod. 2020;35(Suppl 1)."},{"key":"1790_CR22","doi-asserted-by":"crossref","unstructured":"Al-Hendy A, Lukes AS, Poindexter A, et al. LIBERTY: Long-term extension study demonstrating one-year efficacy and safety of relugolix combination therapy in women with symptomatic uterine fibroids [abstract no. O-1]. Fertil Steril. 2020;114(Suppl 3):e1.","DOI":"10.1016\/j.fertnstert.2020.08.027"},{"key":"1790_CR23","doi-asserted-by":"crossref","unstructured":"Venturella R, Al-Hendy A, Nyirady T, et al. Relugolix combination therapy in European women with symptomatic uterine fibroids in the liberty long-term extension (LTE) study [abstract no. 69]. Eur J Obstet Gynecol Reprod Biol. 2022;270:e32.","DOI":"10.1016\/j.ejogrb.2021.11.130"},{"key":"1790_CR24","doi-asserted-by":"crossref","unstructured":"Al-Hendy A, Venturella R, Arjona Ferreira JC, et al. Liberty randomized withdrawal study: 2-year efficacy and safety of relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids [abstract no. O-5]. Fertil Steril. 2021;116(Suppl 3):e2.","DOI":"10.1016\/j.fertnstert.2021.07.014"},{"key":"1790_CR25","unstructured":"McClung MR, Santora A, Al-Hendy A, et al. Evaluation of relugolix combination therapy to maintain bone mass in women with uterine fibroids through 52 weeks: LIBERTY long-term extension study [abstract no. P-639]. J Bone Miner Res. 2020;35(Suppl 1):245\u20136."},{"key":"1790_CR26","doi-asserted-by":"crossref","unstructured":"McClung MR, Lukes AS, Venturella R, et al. Effects of relugolix combination therapy on bone mineral density through 2 years in women with heavy menstrual bleeding associated with uterine fibroids [abstract no. O-30]. Fertil Steril. 2021;116(Suppl 3):e13.","DOI":"10.1016\/j.fertnstert.2021.07.043"},{"key":"1790_CR27","unstructured":"McClung MR, Santora A, Al-Hendy A, et al. A prospective observational study of bone mineral density in premenopausal women with uterine fibroids [abstract no. P-552]. J Bone Miner Res. 2020;35(Suppl 1):220."},{"key":"1790_CR28","unstructured":"AbbVie Inc. Oriahnn\u00ae (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), co-packaged for oral use: US prescribing information. 2020. https:\/\/www.oriahnn.com\/. Accessed 21 Sept 2022."},{"key":"1790_CR29","unstructured":"European Medicines Agency. Esmya 5 mg tablets: EU summary of product characteristics. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ryeqo-epar-product-information_en.pdf. Accessed 21 Sept 2022."},{"issue":"1","key":"1790_CR30","first-page":"286","volume":"3","author":"E Hunsche","year":"2022","unstructured":"Hunsche E, Rakov V, Scippa K, et al. The burden of uterine fibroids from the perspective of US women participating in open-ended interviews. Womens Health Rep (New Rochelle). 2022;3(1):286\u201396.","journal-title":"Womens Health Rep (New Rochelle)."},{"key":"1790_CR31","doi-asserted-by":"publisher","unstructured":"Hartmann KE, Fonnesbeck C, Surawicz T, et al. Management of uterine fibroids. Comparative effectiveness review no. 195. AHRQ Publication No 17(18)-EHC028-EF. 2017. https:\/\/doi.org\/10.23970\/AHRQEPCCER195.","DOI":"10.23970\/AHRQEPCCER195"},{"issue":"3","key":"1790_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/1471-0528.16928","volume":"129","author":"A Amoah","year":"2022","unstructured":"Amoah A, Joseph N, Reap S, et al. Appraisal of national and international uterine fibroid management guidelines: a systematic review. BJOG. 2022;129(3):356\u201364.","journal-title":"BJOG"},{"key":"1790_CR33","unstructured":"National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management: NICE guideline [NG88]. 2018. https:\/\/www.nice.org.uk\/. Accessed 21 Sept 2022."}],"updated-by":[{"DOI":"10.1007\/s40265-022-01814-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01790-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01790-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01790-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T20:09:24Z","timestamp":1700078964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01790-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1790"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01790-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-022-01814-z","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"26 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Digital Features for this Adis Drug Evaluation, including a peer-reviewed video abstract, can be found at","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.6084\/m9.figshare.20765737","URL":"https:\/\/doi.org\/10.6084\/m9.figshare.20765737","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-022-01814-z","URL":"https:\/\/doi.org\/10.1007\/s40265-022-01814-z","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}